Medtech

Reimbursement strategies are crucial for establishing or improving the financial viability of medical technologies. They rely on a comprehensive analysis that includes procedure coding, payment mechanisms, tariffs, policies, similar analog devices and technologies.

These strategies are essential in various scenarios, such as when new technologies lack coding and reimbursement, when existing tariffs are insufficient, or when there are usage restrictions despite sufficient tariffs.

Data requirements for medical devices are not as transparent as they are for pharmaceuticals.

RPN’s expertise covers clinical, technological, and economic areas. This ensures that diverse reimbursement and health economics and outcomes research (HEOR) projects across European countries are handled and a broad understanding of the reimbursement landscape for different medical technologies is gained.

Stakeholders’ interviews will also be used to determine evidence and features that influence reimbursement decisions.

Our services span across a wide range of medical devices, medical technologies, and In-Vitro Diagnostics (IVD) tests.

Health economics plays a pivotal role in establishing the cost-effectiveness of medical technologies in healthcare systems.

While initial economic models typically refer to the UK market, expansion into various European regions necessitates tailored adaptations to meet local payer and Health Technology Assessment (HTA) requirements.

As healthcare systems and economic evaluations differ significantly across countries, RPN offers market access and HEOR services to align health economic models with the specific needs of diverse EU stakeholders.

RPN stands at the forefront of this specialization, delivering two key services:

• Providing essential data for client-led model adaptations and managing full model adaptations.
• Encompassing data collection, analysis, and comprehensive report development.

These services are designed to support medical technologies in navigating market access processes, ensuring that the health economic evidence resonates with the economic and clinical realities of each unique healthcare system across Europe.

RPN supports in the interactions with the different bodies involved in the HTA assessment process of the medical device across Europe.